Vanucizumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized |
Target | angiopoietin 2 |
Clinical data | |
Other names | RG7221 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6529H10033N1733O2038S46 |
Molar mass | 146887.94 g·mol−1 |
Vanucizumab (INN; development code RG7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer.[1][2]
Vanucizumab is a bi-specific monoclonal antibody composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding Vascular Endothelial Growth Factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone.
This drug was developed by Genentech/Roche.
References[]
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Vanucizumab, American Medical Association.
- ^ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).
Categories:
- Drugs not assigned an ATC code
- Monoclonal antibody stubs
- Monoclonal antibodies
- Experimental cancer drugs